Stroke is the second leading cause of death and the third leading cause of disability worldwide.
A stroke occurs when blow flow to part of the brain is reduced or cut off as a result of a blood clot and causes cell death.
The use of mechanical devices to remove blood clots (thrombectomy) has become the standard of care for the treatment of acute ischemic stroke patients with large vessel occlusions. The purpose of these devices – stent retrievers and aspiration catheters – is to quickly extract clots, restore blood flow (revascularization), and achieve good clinical outcomes.
Despite technological advances with current thrombectomy devices, successful revascularization is not always feasible (Neurosurgical Focus, 42:4, April 2017).
Today, physicians are forced to choose between deploying expensive, cumbersome stent retrievers that may increase the risk of emboli release or taking a quicker approach: inserting aspiration catheters that are difficult to “steer” and advance through the arteries and have limited ability to provide efficient aspiration.
According to Lawrence Biegelsen, a senior analyst at Wells Fargo Securities (“DAWN Trial Likely Positive for Stroke Market,” March 2017), in the United States alone there are over 290,000 ischemic stroke patients with large vessel occlusion. This number is expected to grow to > 330,000 by 2021. There is great potential in this market as it is under-served. In 2016, only 23,000 stroke thrombectomy procedures were performed, with expected number of procedures to exceed 49,000 by 2021.
CathTrap is a uniquely designed aspiration based neurothrombectomy system that quickly and efficiently extracts blood clots from large vessels in the brain and restores blood flow.
With the catheter’s proprietary large bore funnel and closure tip, the CathTrap aspiration catheter securely removes the entire clot in one pass.
All in one system
Clot trapping inside the funnel
Proximal and distal embolic protection